The US Food and Drug Administration (FDA) has granted approval for Sagent Pharmaceuticals’ bupivacaine hydrochloride injection.
The drug is indicated for the production of local or regional anaesthesia or analgaesia for dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures.
Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Recognised with 2025 Excellence Awards for Research and Development and Marketing, Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.
